Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
Atea Pharmaceuticals, Inc. AVIR, a clinical-stage company, reported positive initial data from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir and ruza...